DJIA 17,745.98 -5.41 -0.03%
NASDAQ 5,128.79 17.05 0.33%
S&P 500 2,108.63 0.06 0.00%
market minute promo


company name or ticker

Will Acceleron (XLRN) Continue to Surge Higher? - Tale of the Tape

Acceleron Pharma's (XLRN) CEO John Knopf on Q3 2014 Results - Earnings Call Transcript

Acceleron Pharma Is Due For A Market Correction And Is An Attractive Short Candidate During The Comi

Acceleron Pharma Is Due For A Market Correction And Is An Attractive Short Candidate During The Coming Months

A Quick Look at Celgene Corporation's Drug Development Pipeline

Celgene's drug development pipeline is currently firing on all cylinders; but can it stay that way for long? Find out as we take a closer look at the experimental drugs which matter most to Celgene.

Sector Update: Health-care Stocks Higher Pre-Bell

Sector Update: Health Care

Acceleron Initiates Phase 1 Clinical Trial With Innovative Muscle Drug ACE-083

Acceleron Hit Over Competitive Concerns, But Investors Overlook Rest of Pipeline

Will Acceleron (XLRN) Continue to Surge Higher? - Tale of the Tape

Acceleron Pharma (XLRN) Jumps: Stock Rises 12.8% - Tale of the Tape

See More Articles...